Bellerophon Therapeutics (BLPH) CEO Peacock to Retire; Successor Named

September 20, 2016 6:34 AM EDT
Get Alerts BLPH Hot Sheet
Trade BLPH Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) announced the planned transition of Fabian Tenenbaum, current Chief Financial Officer and Chief Business Officer, to Chief Executive Officer of the company, succeeding Jonathan Peacock, who will retain his position as Chairman of the Board and remain actively involved. The transition will be completed by year-end.

Commenting on the management transition, Mr. Peacock noted:

“Bellerophon has made significant clinical progress of late, most recently having dosed the first patient in its Phase 3 program for the INOpulse® delivery system for patients with Pulmonary Arterial Hypertension (PAH), as well as having dosed the first patient in our Phase 2 trial in patients with pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF). In addition, plans are in place to complete further Phase 2 clinical testing for patients suffering from pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD).

“I am confident that we will have a seamless transition as Fabian and our experienced leadership team continue to execute on these programs. I intend to stay actively involved in the business as Chairman and look forward to us bringing INOpulse therapies to market for these underserved patients.”

Mr. Tenenbaum noted, “I am honored to have been chosen to succeed Jon as CEO. I look forward to continuing to work with our leadership team, lead investigators and other partners to execute on our clinical trials and move the company toward commercialization.”

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Hot Corp. News, Management Changes, Management Comments

Add Your Comment